Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1115 |
Name | sarcoma |
Definition | A cell type cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3936 |
Path | disease disease of cellular proliferation cancer cell type cancer sarcoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00356031 | Phase II | Bevacizumab | Bevacizumab and Radiation Therapy for Sarcomas | Completed | USA | 0 |
NCT00902044 | Phase I | Fludarabine Cyclophosphamide HER2 sensitized T-cells | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT01005797 | Phase I | Panobinostat + Sorafenib | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | Completed | USA | 0 |
NCT01010958 | Phase I | Valproic acid | Adjuvant Valproate for High Grade Sarcomas | Terminated | USA | 0 |
NCT01106872 | Phase Ib/II | Bevacizumab + Docetaxel + Gemcitabine + Valproic acid | Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas | Completed | USA | 0 |
NCT01154452 | Phase Ib/II | Vismodegib RO4929097 + Vismodegib RO4929097 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | Completed | USA | 0 |
NCT01189643 | Phase I | Bevacizumab + Irinotecan + Temozolomide | Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor | Active, not recruiting | USA | 0 |
NCT01294670 | Phase Ib/II | Etoposide + Vorinostat | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | 2 |
NCT01418001 | Phase Ib/II | Docetaxel + Gemcitabine + Pazopanib | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | Terminated | USA | 0 |
NCT01438554 | Phase I | Pazopanib + Trametinib | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | USA | 0 |
NCT01446809 | Phase I | Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib | Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01468922 | Phase I | Tivantinib Pazopanib | Pazopanib and ARQ 197 for Advanced Solid Tumors | Completed | USA | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01532687 | Phase II | Gemcitabine Gemcitabine + Pazopanib | Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01593748 | Phase II | Docetaxel + Gemcitabine Gemcitabine + Pazopanib | A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01643278 | Phase I | Dasatinib + Ipilimumab | Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic | Completed | USA | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | 5 |
NCT01719302 | Phase Ib/II | Docetaxel + Gemcitabine + Pazopanib | Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01719744 | Phase II | ENMD-2076 | Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | Completed | CAN | 0 |
NCT01746238 | Phase I | Bevacizumab + Doxorubicin | Bevacizumab/Doxorubicin/Radiation for Sarcoma | Active, not recruiting | USA | 0 |
NCT01755195 | Phase II | Cabozantinib | Cabozantinib for Adults With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT01879085 | Phase Ib/II | Gemcitabine Docetaxel Pegfilgrastim Vorinostat | Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT01946529 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Bevacizumab + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Sorafenib + Temozolomide + Temsirolimus + Vincristine Sulfate | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | Active, not recruiting | USA | 0 |
NCT01975519 | Phase I | Carotuximab + Pazopanib | A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02008877 | Phase Ib/II | Ganetespib + Sirolimus | A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST | Completed | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02049905 | Phase III | Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Completed | USA | CAN | 11 |
NCT02050919 | Phase II | Epirubicin + Ifosfamide + Sorafenib | Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT02066181 | Phase III | Sorafenib | Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis | Active, not recruiting | USA | CAN | 0 |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02130869 | Phase I | Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02180698 | Phase I | GLA-SE | TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02180867 | Phase II | Pazopanib Doxorubicin + Ifosfamide | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS) | Active, not recruiting | USA | CAN | 1 |
NCT02192541 | Phase I | Aflibercept + Ganetespib | Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | Terminated | USA | 0 |
NCT02267083 | Phase II | Camsirubicin | Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02300545 | Phase II | Pazopanib | Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | Completed | USA | 0 |
NCT02319824 | Phase I | NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy | Completed | USA | 0 | |
NCT02323191 | Phase I | Atezolizumab + Emactuzumab | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | 3 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Recruiting | USA | 0 |
NCT02357810 | Phase II | Pazopanib + Topotecan | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Active, not recruiting | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02423863 | Phase II | Poly ICLC | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02446431 | Phase I | Cyclophosphamide Bevacizumab Temsirolimus Valproic acid | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Recruiting | USA | 0 |
NCT02451943 | Phase III | Olaratumab Doxorubicin | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Active, not recruiting | USA | CAN | 23 |
NCT02453191 | Phase Ib/II | Talimogene laherparepvec | TVEC and Preop Radiation for Sarcoma | Active, not recruiting | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02500797 | Phase II | Ipilimumab Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma | Active, not recruiting | USA | 0 |
NCT02508038 | Phase I | Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa | Recruiting | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | CAN | 2 |
NCT02558140 | Phase I | RG7386 | A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 2 |
NCT02574728 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | Recruiting | USA | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Recruiting | USA | CAN | 28 |
NCT02584309 | Phase II | Dexrazoxane Doxorubicin + Olaratumab | Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT02584647 | Phase Ib/II | Pexidartinib + Sirolimus | Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2) | Recruiting | USA | 0 |
NCT02601209 | Phase Ib/II | Pazopanib Sapanisertib | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | 1 |
NCT02628535 | Phase I | MGD009 | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | 1 |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | CAN | 0 |
NCT02636725 | Phase II | Axitinib + Pembrolizumab | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Active, not recruiting | USA | 7 |
NCT02640508 | Phase II | Eribulin + Lenvatinib | Eribulin and Lenvatinib in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Recruiting | USA | 0 |
NCT02659020 | Phase Ib/II | Olaratumab Docetaxel + Gemcitabine | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 9 |
NCT02783599 | Phase I | Doxorubicin + Olaratumab | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | Completed | USA | 4 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | 3 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Recruiting | USA | 0 |
NCT02795819 | Phase I | AR-42 + Pazopanib | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Terminated | USA | 0 |
NCT02815995 | Phase II | Durvalumab + Tremelimumab | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | Active, not recruiting | USA | 0 |
NCT02839694 | Phase I | Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | Withdrawn | 0 | |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT02888665 | Phase Ib/II | Doxorubicin + Pembrolizumab | Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02890758 | Phase I | ALT-803 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Recruiting | USA | 0 |
NCT02900651 | Phase Ib/II | MAK683 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Recruiting | USA | CAN | 7 |
NCT02987959 | Phase II | Sapanisertib | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03042819 | Phase I | Doxorubicin + Selinexor | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | Active, not recruiting | CAN | 0 |
NCT03056001 | Phase II | Doxorubicin + Pembrolizumab | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | Active, not recruiting | USA | 0 |
NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03069378 | Phase II | Pembrolizumab + Talimogene laherparepvec | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03092323 | Phase II | Pembrolizumab | A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) | Recruiting | USA | CAN | 2 |
NCT03116529 | Phase Ib/II | Durvalumab + Tremelimumab | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma (NEXIS) | Recruiting | USA | 0 |
NCT03126591 | Phase I | Olaratumab + Pembrolizumab | A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Active, not recruiting | USA | 3 |
NCT03138161 | Phase Ib/II | Ipilimumab + Nivolumab + Trabectedin | Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03139331 | Phase I | Irinotecan + Pazopanib + Temozolomide | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | Completed | USA | 0 |
NCT03149120 | Phase II | Nivolumab Nivolumab + Pazopanib | Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | Withdrawn | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | 1 |
NCT03168061 | Phase Ib/II | NC-6300 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03217266 | Phase I | KRT-232 | MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03283696 | Phase I | Doxorubicin + Ifosfamide + Mesna + Olaratumab | A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | 2 |
NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT03338959 | Phase Ib/II | Pembrolizumab | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03365791 | Phase II | LAG525 Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03397186 | Phase II | Trabectedin | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | Withdrawn | USA | 0 |
NCT03414229 | Phase II | Epacadostat + Pembrolizumab | A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
NCT03441360 | Phase II | Eribulin | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) | Recruiting | USA | 0 |
NCT03449108 | Phase II | Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna | Iovance Alliance: LN-145 Across Multiple Tumor Types | Recruiting | USA | 0 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) | Recruiting | USA | CAN | 1 |
NCT03449901 | Phase II | ADI-PEG 20 + Docetaxel + Gemcitabine | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Recruiting | USA | 1 |
NCT03463408 | Phase I | Ipilimumab + Nivolumab | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03465592 | Phase Ib/II | Nivolumab | Trial of Nivolumab Following Partially HLA Mismatched BMT in Children & Adults With Sarcoma | Recruiting | USA | 0 |
NCT03474640 | Phase I | Toripalimab | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT03478462 | Phase I | CLR 131 | Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | Recruiting | USA | CAN | 1 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT03660930 | Phase Ib/II | Nab-Rapamycin + Pazopanib | Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Patients With Nonadipocytic Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT03670069 | Phase I | Itacitinib | Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT03719430 | Phase II | APX005M + Doxorubicin + Olaratumab | APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma | Recruiting | USA | 0 |
NCT03727789 | Phase I | CBL0137 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Recruiting | USA | 0 |
NCT03778996 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 | SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients (HopES) | Recruiting | USA | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Recruiting | USA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Recruiting | USA | 0 |
NCT03880123 | Phase I | Ixazomib + Selinexor | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Withdrawn | USA | 0 |
NCT03886311 | Phase II | Nivolumab + Talimogene laherparepvec + Trabectedin | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) | Recruiting | USA | 0 |
NCT03899805 | Phase II | Eribulin + Pembrolizumab | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03994627 | Expanded access | Olaratumab | Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma | Available | USA | CAN | 9 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04040205 | Phase II | Abemaciclib | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Recruiting | USA | 0 |
NCT04076579 | Phase II | Olaparib + Trabectedin | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | Recruiting | USA | 0 |
NCT04095221 | Phase Ib/II | Irinotecan + Prexasertib + Temozolomide | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | Recruiting | USA | 0 |
NCT04118166 | Phase II | Ipilimumab + Nivolumab | Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | 0 |
NCT04145349 | Phase Ib/II | Cyclophosphamide + Vinorelbine Cyclophosphamide + Ramucirumab + Vinorelbine | CAMFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | Recruiting | USA | 9 |
NCT04145622 | Phase Ib/II | DS-7300a | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04165330 | Phase Ib/II | Anlotinib + Nivolumab | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Recruiting | USA | 0 |
NCT04199026 | Phase I | Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | Not yet recruiting | USA | 0 |
NCT04200443 | Phase II | Cabozantinib + Temozolomide | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04204941 | Phase III | Doxorubicin Doxorubicin + Tazemetostat | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | Recruiting | USA | CAN | 2 |
NCT04220229 | Phase Ib/II | Cabozantinib | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | Recruiting | USA | 0 |
NCT04242238 | Phase I | Avelumab + DCC-3014 | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | Recruiting | USA | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04332874 | Phase II | Pembrolizumab | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | Recruiting | USA | 0 |
NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04441099 | Phase Ib/II | NBE-002 | NBE-002 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |
NCT04478279 | Phase Ib/II | ST-101 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04480502 | Phase II | Envafolimab + Ipilimumab Envafolimab | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC) | Recruiting | USA | 0 |
NCT04535713 | Phase II | Docetaxel + Doxorubicin + Gemcitabine + Nivolumab | Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | Recruiting | USA | 0 |
NCT04551430 | Phase II | Cabozantinib + Ipilimumab + Nivolumab Cabozantinib | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04577014 | Phase Ib/II | Docetaxel + Gemcitabine + Retifanlimab | INCMGA00012 (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04599062 | Phase Ib/II | Talimogene laherparepvec | TVEC and Preop Radiation for Sarcoma (8 ml Dose) | Recruiting | USA | 0 |
NCT04648826 | Phase Ib/II | Azacitidine + M7824 | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | Not yet recruiting | USA | 0 |